REGN Stock Price Today (October 2026) — Regeneron Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-07
Regeneron Pharmaceuticals, Inc. (REGN) is trading at $742.12, up 0.46% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $853.19 (15.0% upside).
- Volatility is low (23.15% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (16.70% YoY) alongside competitive pressures in the Biotechnology space.
REGN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Regeneron Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $71.12B
P/E Ratio
Forward P/E: 13.18
Revenue Growth
Year over Year
Analyst Target
+15.0% upside potential
Key Investor Questions About REGN
What investors need to know before buying
Based on current market data, REGN presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 37.47)
- Fundamentals say: Looking solid (debt and growth supportive)
REGN's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for REGN investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.71B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, REGN stock traded between $541.00 and $859.34 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.15% annualized volatility and β=0.68, the stock exhibits low sensitivity to market moves—making REGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run
Regeneron Pharmaceuticals has delivered a strong share price run over the past year, which puts a spotlight on whether the current US$801.82 level is still grounded in what the business earns today. With the focus squarely on profits and the P/E discussion around them, the question is how much of that recent strength can be explained by earnings power rather than sentiment alone. The stock has returned 39.7% over the past year. This puts real pressure on the valuation case to be supported by...
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch. Chris Fenimore, Regeneron’s executive vice
Is Regeneron Stock a Bargain Below $800?
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion
Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
In September 2026, several law firms, including Bronstein, Gewirtz & Grossman and Robbins Geller Rudman & Dowd, filed federal securities class action lawsuits against Regeneron Pharmaceuticals, alleging that management misled investors about key design assumptions and clinical prospects for its Phase III Fianlimab-Libtayo oncology trial. The complaints center on claims that Regeneron understated the risk that Fianlimab-Libtayo would fail to show meaningful benefit over standard therapies,...
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit News
Regeneron Pharmaceuticals (REGN) is back in focus after law firm Bronstein, Gewirtz & Grossman announced a securities class action tied to disclosures around the Phase III Fianlimab Libtayo trial. Recent trading tells a mixed story for Regeneron Pharmaceuticals. The share price is up 29.12% over the past 90 days and the 1 year total shareholder return is 39.33%, even though the 7 day share price return is down 4.11% as investors weigh the lawsuit headlines against a longer trend of positive...
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
Explore More Analysis for REGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 30, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $742.12. The RSI (14-day) is at 37.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $853.19 implies 15.0% upside from current levels. Volatility is moderate at 23.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Regeneron Pharmaceuticals, Inc. (REGN): The trailing P/E ratio is 19.64, which is in line with broader market averages. The forward P/E is 13.18, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.33, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.51. Price-to-Sales is 5.17. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering REGN, the consensus price target is $853.19. This represents a 15.0% upside from the current price of $742.12. The range spans from a low target of $730.00 to a high target of $1030.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a current yield of approximately 0.51%. The annualized dividend rate is $3.64 per share. The payout ratio is 9.0%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 18, 2026.
Key risks for Regeneron Pharmaceuticals, Inc. (REGN) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Regeneron Pharmaceuticals, Inc.'s (REGN) current debt and financial health profile: Total debt stands at $2.71B. The debt-to-equity ratio is 0.09x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.34, indicating strong short-term liquidity. The quick ratio is 2.63. The company holds $7.99B in cash and equivalents. Free cash flow is positive at $3.07B, providing a cushion for debt servicing and shareholder returns.